24 February 2018
News and Views
Links and Services
The latest issue of the Annals of Internal Medicine investigates long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus.
The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors